Mga Batayang Estadistika
| CIK | 1165320 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to GB Sciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (Ex |
|
| February 12, 2025 |
SEC File Number: 000-55462 CUSIP Number: 361544109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (Exact |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (E |
|
| November 14, 2024 |
SEC File Number: 000-55462 CUSIP Number: 361544109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 15, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commissio |
|
| October 15, 2024 |
Exhibit 99.1 GB Sciences Signs Licensing Deal with EndoPure Life Sciences for 5% Gross Sales Royalty & Sponsorship of First-in-Human Trial for their Cannabinoid-based Parkinson’s Drug As a part of their Exclusive Licensing Deal, EndoPure Life Sciences will finance and sponsor first-in-human clinical trials, which help to advance GB Sciences’ cannabinoid-based products globally. Las Vegas, NV/ ACCE |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 14, 2024 |
SEC File Number: 000-55462 CUSIP Number: 361544109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission Fil |
|
| July 1, 2024 |
SEC File Number: 000-55462 CUSIP Number: 361544109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission Fil |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (Ex |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (E |
|
| November 14, 2023 |
SEC File Number: 000-55462 CUSIP Number: 361544109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 10, 2023 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-227452 PROSPECTUS SUPPLEMENT NO. 5 (To the Prospectus dated March 8, 2019) GB SCIENCES, INC. 64,053,812 Shares of Common Stock This Prospectus Supplement No. 5 supplements the prospectus dated March 8, 2019 (the “Prospectus”), relating to the resale of up to 64,053,812 shares of common stock of GB Sciences, Inc. by the selling stockholders iden |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada 000-55462 59-3733133 (State or other Jurisdiction of Incorporation or organization) |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB SCIE |
|
| July 14, 2023 |
Amendment to Articles of Incorporation Exhibit 3.5 |
|
| July 14, 2023 |
Exhibit 21.1 Subsidiaries of GB Sciences, Inc. GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC GB Sciences Texas, LLC |
|
| July 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (Exact name of registra |
|
| June 30, 2023 |
SEC File Number: 000-55462 CUSIP Number: 361544109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2023 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission Fi |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission Fil |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Information Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission O |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Information Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commis |
|
| December 14, 2022 |
PRE 14A 1 gblx20221130pre14a.htm FORM PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Information Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Information S |
|
| November 10, 2022 |
424B3 1 gblx20221024424b3.htm FORM 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-227452 PROSPECTUS SUPPLEMENT NO. 4 (To the Prospectus dated March 8, 2019) GB SCIENCES, INC. 64,053,812 Shares of Common Stock This Prospectus Supplement No. 4 supplements the prospectus dated March 8, 2019 (the “Prospectus”), relating to the resale of up to 64,053,812 shares of common stock of GB Scienc |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB |
|
| November 9, 2022 |
$300,000 Note Extension Agreement between Registrant and Dickinson Hughes, LLC Exhibit 10.1 $300,000 NOTE EXTENSION AGREEMENT This $300,000 Note Extension Agreement (the ?Agreement?) is made by and between Dickinson Hughes LLC (the ?Note Holder?), and GB Sciences, Inc. (the ?Company?). The Note Holder and the Company are sometimes referred to hereinafter as the ?Parties?). WHEREAS on February 23, 2021, the Company issued to the Note Holder a note in the face amount of $300,0 |
|
| November 9, 2022 |
$560,000 Note Extension Agreement between Registrant and Robert Moody, Jr. Exhibit 10.2 $560,000 NOTE EXTENSION AGREEMENT This $560,000 Note Extension Agreement (the ?Agreement?) is made by and between Robert Moody Jr. (the ?Note Holder?), and GB Sciences, Inc. (the ?Company?). The Note Holder and the Company are sometimes referred to hereinafter as the ?Parties?). WHEREAS on August 3, 2017, the Company issued to the Note Holder a note in the face amount of $560,000 (the |
|
| August 30, 2022 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2022 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission F |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB SCIE |
|
| June 30, 2022 |
Exhibit 10.15 PROMISSORY NOTE $3,025,000 December 31, 2021 FOR VALUE RECEIVED, AJE MANAGEMENT, LLC (?Maker?), hereby promises to pay to GB SCIENCES, INC., a Nevada corporation (?Payee?), with an address at 3550 W. Teco Avenue, Las Vegas Nevada 89118, the principal sum of THREE MILLION TWENTY FIVE THOUSAND DOLLARS ($3,025,000), together with all interest that has accrued thereon in accordance with |
|
| June 30, 2022 |
Exhibit 4.6 Common Stock The holders of common stock are entitled to one vote per share on all matters to be voted on by stockholders and are entitled to receive such dividends, if any, as may be declared from time to time by our board of directors from funds legally available therefore, subject to the dividend preferences of the preferred stock, if any. Upon our liquidation or dissolution, the ho |
|
| June 30, 2022 |
Exhibit 10.14 SECOND PROMISSORY NOTE MODIFICATION AGREEMENT THIS SECOND PROMISSORY NOTE MODIFICATION AGREEMENT (this ?Second Modification?), dated this 4th day of March, 2022 (the ?Effective Date?), is entered into by GB SCIENCES, INC. (the ?Company?), and 483 MANAGEMENT, LLC (?483?). Hereinafter the Company and 483 are sometimes referred to jointly as the ?Parties?. WHEREAS, 483 is the holder of |
|
| June 30, 2022 |
Exhibit 21.1 Subsidiaries of GB Sciences, Inc. GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC GB Sciences Texas, LLC |
|
| June 30, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K FORM 10-K Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (Exact name o |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 333-82580 CUSIP Number 361-544109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ?Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For period ended: March 31, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transi |
|
| March 16, 2022 |
Exhibit 99.01 A MESSAGE FROM BOTH THE PRESIDENT AND THE CHAIRMAN OF GB SCIENCES, INC. To Our Shareholders: 2021 was a transformational year for Gb Sciences. In December 2021, we sold our last cannabis production facility to become a pure-play biopharmaceutical company specializing in cannabis- and plant-inspired medicines for the prescription drug market. This sale greatly reduced our debt burden |
|
| March 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission Fi |
|
| March 16, 2022 |
Exhibit 99.03 Gb Sciences Issues Summary Shareholder Letter Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021. LAS VEGAS, March 15, 2022 (Newswire.com) - Gb Sciences, Inc., a leading cannabis- and plant-inspired biopharmaceutical research and development company, today issued a letter to sharehold |
|
| March 16, 2022 |
Exhibit 99.02 Gb Sciences Issues Shareholder Letter Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021. LAS VEGAS, March 16, 2022 (Newswire.com) - Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, issued a letter to shareholde |
|
| March 10, 2022 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-227452 PROSPECTUS SUPPLEMENT NO. 3 (To the Prospectus dated March 8, 2019) GB SCIENCES, INC. 64,053,812 Shares of Common Stock This Prospectus Supplement No. 3 supplements the prospectus dated March 8, 2019 (the ?Prospectus?), relating to the resale of up to 64,053,812 shares of common stock of GB Sciences, Inc. by the selling stockholders iden |
|
| February 11, 2022 |
PROMISSORY NOTE $3,025,000 December 31, 2021 FOR VALUE RECEIVED, AJE MANAGEMENT, LLC (?Maker?), hereby promises to pay to GB SCIENCES, INC. |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB |
|
| January 6, 2022 |
Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2021 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB |
|
| September 24, 2021 |
September 24, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 21, 2021 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-227452 PROSPECTUS SUPPLEMENT NO. 2 (To the Prospectus dated March 8, 2019) GB SCIENCES, INC. 64,053,812 Shares of Common Stock This Prospectus Supplement No. 2 supplements the prospectus dated March 8, 2019 (the ?Prospectus?), relating to the resale of up to 64,053,812 shares of common stock of GB Sciences, Inc. by the selling stockholders iden |
|
| September 17, 2021 |
Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GB SCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) 59-3733133 (I.R.S. Employer Identificatio |
|
| September 17, 2021 |
Exhibit 4.4 GB SCIENCES, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS TO BE EFFECTIVE AS OF SEPTEMBER 17, 2021 1. GENERAL. (a) Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive Awards. (b) Available Awards. The Plan provides for the grant of the following types of Awards: (i) Incentive Stock Options, and (ii) Nonstatutory Stock Options. (c |
|
| September 17, 2021 |
As filed with the Securities and Exchange Commission on September 17, 2021 As filed with the Securities and Exchange Commission on September 17, 2021 Registration No. |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2021 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission F |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB SCIE |
|
| July 6, 2021 |
Exhibit 10.30 LOAN AGREEMENT THIS LOAN AGREEMENT (this ?Agreement?), is entered into as of July 24, 2020 (the ?Effective Date?), by and among GB Sciences Las Vegas, LLC, a Nevada limited liability company (?GBS LV?), GB Sciences Nevada LLC, a Nevada limited liability company (?GBS NV? and together with GBS LV, the ?Borrowers?), and AJE Management LLC, a California limited liability company (the ?L |
|
| July 6, 2021 |
Exhibit 10.42 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the ?Agreement?) is made by and between Andrea Small-Howard (the ?Director?) and GB Sciences, Inc., a Nevada corporation (the ?Company?) (jointly the ?Parties?). Recitals A. The Director is or was a member of the board of directors (the ?Board?) of the Company. B. The Company does not at this time and has not at prior times du |
|
| July 6, 2021 |
Exhibit 10.29 AMENDMENT NO. 2 TO MEMBERSHIP INTEREST PURCHASE AGREEMENT THIS AMENDMENT NO. 2 TO MEMBERSHIP INTEREST PURCHASE AGREEMENT (this ?Amendment?), dated as of July 24, 2020, is made and entered into, by and between GB Sciences, Inc. a Nevada corporation (the ?Seller?), GB Sciences Las Vegas, LLC, a Nevada limited liability company (?GBS LV?), GB Sciences Nevada LLC, a Nevada limited liabil |
|
| July 6, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K FORM 10-K Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (Exact name o |
|
| July 6, 2021 |
Exhibit 10.34 AMENDMENT TO MEMBERSHIP INTEREST PURCHASE AGREEMENT This Amendment to that certain Membership Interest Purchase Agreement (the "Amendment") with an effective date of January 1, 2020 by and among Wellcana Plus, LLC, a Louisiana limited liability company ("Purchaser"), GB Sciences, Inc. a Nevada corporation ("Seller"), GB Sciences Louisiana, LLC, a Louisiana limited liability company ( |
|
| July 6, 2021 |
Exhibit 10.43 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the ?Agreement?) is made by and between Zach Swarts (the ?Officer?) and GB Sciences, Inc., a Nevada corporation (the ?Company?) (jointly the ?Parties?). Recitals A. The Officer is serving as the Chief Financial Officer of the Company. B. The Company does not at this time have directors and officers and insurance (?D&O Insuranc |
|
| July 6, 2021 |
Indemnification Agreement between Registrant and Leslie Bocskor dated November 16, 2020 Exhibit 10.40 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the ?Agreement?) is made by and between Leslie Bocskor (the ?Director?) and GB Sciences, Inc., a Nevada corporation (the ?Company?) (jointly the ?Parties?). Recitals A. The Director is or was a member of the board of directors (the ?Board?) of the Company. B. The Company does not at this time and has not at prior times during |
|
| July 6, 2021 |
Exhibit 10.37 MANAGEMENT SERVICES AGREEMENT THIS MANAGEMENT SERVICES AGREEMENT (this ?Agreement?), effective as of August 10, 2020 (the ?Effective Date?), is made by and between GB Sciences, Inc. a Nevada corporation (the ?Company?), GB Sciences Nopah LLC, a Nevada limited liability company (?Nopah?), Nopah 5, LLC, a Nevada limited liability company (together with the Company and Nopah the ?Nopah |
|
| July 6, 2021 |
Exhibit 10.35 JUDGMENT SETTLEMENT AGREEMENT This Judgment Settlement Agreement (this ?Agreement?) is entered into as of November 20, 2020 (the ?Effective Date?) by and among Iliad Research and Trading, L.P., a Utah limited partnership (?Lender?), GB Sciences, Inc., a Nevada corporation (?Borrower?), and solely with respect to Section 3 below, Wellcana Plus LLC, a Louisiana limited liability compan |
|
| July 6, 2021 |
Security Agreement between Registrant and AJE Management, LLC, dated July 24, 2020 Exhibit 10.32 SECURITY AGREEMENT This Security Agreement (this ?Agreement?) is made and entered into effective as of July 24, 2020, by GB SCIENCES NEVADA LLC, a Nevada limited liability company (?GBSN?) and GB SCIENCES LAS VEGAS LLC, a Nevada limited liability company (?GBSLV? and, together with GBSN, each a ?Grantor?), in favor of AJE MANAGEMENT, LLC (?Secured Party?). RECITALS Secured Party has |
|
| July 6, 2021 |
Exhibit 10.28 AMENDMENT TO MEMBERSHIP INTEREST PURCHASE AGREEMENT THIS AMENDMENT TO MEMBERSHIP INTEREST PURCHASE AGREEMENT(this ?Amendment?), dated as of May 11, 2020, is made and entered into, by and between GB Sciences, Inc. a Nevada corporation (the ?Seller?), GB Sciences Las Vegas, LLC, a Nevada limited liability company (?GBS LV?), GB Sciences Nevada LLC, a Nevada limited liability company (? |
|
| July 6, 2021 |
Exhibit 10.41 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the ?Agreement?) is made by and between John Poss (the ?Director?) and GB Sciences, Inc., a Nevada corporation (the ?Company?) (jointly the ?Parties?). Recitals A. The Director is or was a member of the board of directors (the ?Board?) of the Company. B. The Company does not at this time and has not at prior times during the D |
|
| July 6, 2021 |
Omnibus Amendment between Registrant, Exhibit 10.33 OMNIBUS AMENDMENT THIS OMNIBUS AMENDMENT (this ?Amendment?), dated as of December 29, 2020, is made and entered into, by and between GB Sciences, Inc. a Nevada corporation (the ?Seller?), GB Sciences Las Vegas, LLC, a Nevada limited liability company (?GBS LV?), GB Sciences Nevada LLC, a Nevada limited liability company (?GBS NV? and together with GBS LV and the Seller, the ?GBS Part |
|
| July 6, 2021 |
Description of Registrant's Securities Exhibit 4.6 Common Stock The holders of common stock are entitled to one vote per share on all matters to be voted on by stockholders and are entitled to receive such dividends, if any, as may be declared from time to time by our board of directors from funds legally available therefore, subject to the dividend preferences of the preferred stock, if any. Upon our liquidation or dissolution, the ho |
|
| July 6, 2021 |
Exhibit 21.1 Subsidiaries of GB Sciences, Inc. GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC GB Sciences Texas, LLC GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC GB Sciences Nopah, LLC |
|
| July 6, 2021 |
Exhibit 10.36 THIS MEMBERSHIP INTEREST PURCHASE AGREEMENT (the ?Agreement?) is made this 10th day of August, 2020 (the ?Effective Date?), by and among GB Sciences Nopah, LLC, a Nevada limited liability company (?Nopah? or ?Company?), and GB Sciences, Inc., a Nevada Corporation and Nopah 5, LLC, a Nevada limited liability company (each a ?Founding Member? and collectively, the ?Founding Members? an |
|
| July 6, 2021 |
Exhibit 10.39 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the ?Agreement?) is made by and between Edmond A. DeFrank (the ?Director?) and GB Sciences, Inc., a Nevada corporation (the ?Company?) (jointly the ?Parties?). Recitals A. The Director is or was a member of the board of directors (the ?Board?) of the Company. B. The Company does not at this time and has not at prior times duri |
|
| July 6, 2021 |
Exhibit 10.38 PROMISSORY NOTE MODIFICATION AGREEMENT THIS PROMISSORY NOTE MODIFICATION AGREEMENT (this ?Modification?), dated this 10th day of August, 2020 (the ?Effective Date?), is entered into by GB SCIENCES, INC. (the ?Company?), and 483 MANAGEMENT, LLC (?483?). WHEREAS, 483 is the holder of that certain Promissory Note issued by the Company, in the principal amount of $700,000, dated October |
|
| July 6, 2021 |
8% Promissory Note Payable to AJE Management, LLC, dated July 24, 2020 Exhibit 10.31 GB SCIENCES LAS VEGAS, LLC GB SCIENCES NEVADA LLC Secured 8% Promissory Note $500,000.00 July 24, 2020 FOR VALUE RECEIVED, GB SCIENCES LAS VEGAS, LLC, a Nevada limited liability company (?GBS LV?), and GB SCIENCES NEVADA LLC, a Nevada limited liability company (?GBS NV? and together with GBS LV, collectively, the ?Borrower?) with their principal executive offices at 3550 W. Teco Aven |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 333-82580 CUSIP Number 361-544109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ?Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For period ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transi |
|
| June 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission Fil |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission File |
|
| February 16, 2021 |
JUDGMENT SETTLEMENT AGREEMENT This Judgment Settlement Agreement (this ?Agreement?) is entered into as of November 20, 2020 (the ?Effective Date?) by and among Iliad Research and Trading, L. |
|
| February 16, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB |
|
| January 28, 2021 |
FORM 424B3 Filed pursuant to Rule 424(b)(3) Registration No. 333-227452 PROSPECTUS SUPPLEMENT NO. 1 (To the Prospectus dated March 8, 2019) GB SCIENCES, INC. 64,053,812 Shares of Common Stock This Prospectus Supplement No. 1 supplements the prospectus dated March 8, 2019 (the “Prospectus”), relating to the resale of up to 64,053,812 shares of common stock of GB Sciences, Inc. by the selling stockh |
|
| December 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission |
|
| November 27, 2020 |
Entry into a Material Definitive Agreement - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2020 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission |
|
| November 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2020 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission |
|
| November 13, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB |
|
| October 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2020 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission |
|
| October 21, 2020 |
Entry into a Material Definitive Agreement - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2020 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission |
|
| October 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2020 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission |
|
| September 2, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB SCIE |
|
| August 28, 2020 |
MANAGEMENT SERVICES AGREEMENT THIS MANAGEMENT SERVICES AGREEMENT (this “Agreement”), effective as of December 6, 2019 (the “Effective Date”), is made by and between GB Sciences, Inc. |
|
| August 28, 2020 |
Description of Registrant's Securities Common Stock The holders of common stock are entitled to one vote per share on all matters to be voted on by stockholders and are entitled to receive such dividends, if any, as may be declared from time to time by our board of directors from funds legally available therefore, subject to the dividend preferences of the preferred stock, if any. |
|
| August 28, 2020 |
Second Amendment to Note Documents between Registrant and CSW Ventures, LP dated November 27, 2019 SECOND AMENDMENT TO NOTE DOCUMENTS THIS SECOND AMENDMENT TO NOTE DOCUMENTS (this “Amendment”), dated as of November 27, 2019, is made and entered into on the terms and conditions hereinafter set forth, by and among GB SCIENCES, INC. |
|
| August 28, 2020 |
Promissory Note payable to John Davis dated November 15, 2019 PROMISSORY NOTE Borrower: GB Sciences, Inc. 3550 W. Teco Ave. Las Vegas, NV 89118 Lender: John B. Davis 2644 Fairway Drive Baton Rouge, LA 70809 Principal Amount: $151,923.07 Effective Date: November 15, 2019 1. For value received, the Borrower promises to pay the Lender at the address identified above or as may be provided in writing to the Borrower, the principal sum of $151,923.07. 2. This Note |
|
| August 28, 2020 |
Amendment to Promissory Note between Registrant and CSW Ventures, LP dated July 12, 2019 AMENDMENT TO PROMISSORY NOTE THIS AMENDMENT TO PROMISSORY NOTE (this “Amendment”), dated as of October 23, 2019, is entered into by and among GB SCIENCES, INC. |
|
| August 28, 2020 |
THIS NOTE AND THE UNDERLYING SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) SHALL HAVE BECOME EFFECTIVE WITH RESPECT THERETO OR (ii) RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER THE ACT IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER NOR IS IN VIOLATION OF ANY APPLICABLE STATE SECURITIES LAWS. |
|
| August 28, 2020 |
Loan Agreement betrween Registrant and AJE Mangement, LLC dated December 3, 2020 LOAN AGREEMENT THIS LOAN AGREEMENT (this “Agreement”), is entered into as of December 3, 2019 (the “Effective Date”), by and among GB Sciences Las Vegas, LLC, a Nevada limited liability company (“GBS LV”), GB Sciences Nevada LLC, a Nevada limited liability company (“GBS NV” and together with GBS LV, the “Borrowers”), and AJE Management LLC, a California limited liability company (the “Lender”). |
|
| August 28, 2020 | ||
| August 28, 2020 | ||
| August 28, 2020 |
Exhibit 21.1 Subsidiaries of GB Sciences, Inc. GB Sciences, LLC GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC ECRX, Inc. GB Sciences Texas, LLC GB Sciences Nopah, LLC GBS Global Biopharma, Inc. |
|
| August 28, 2020 |
THIS NOTE AND THE UNDERLYING SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) SHALL HAVE BECOME EFFECTIVE WITH RESPECT THERETO OR (ii) RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER THE ACT IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER NOR IS IN VIOLATION OF ANY APPLICABLE STATE SECURITIES LAWS. |
|
| August 28, 2020 |
8% Promissory Note payable to AJE Management, LLC GB SCIENCES LAS VEGAS, LLC GB SCIENCES NEVADA LLC 8% Promissory Note $470,000.00 December 3, 2019 FOR VALUE RECEIVED, GB SCIENCES LAS VEGAS, LLC, a Nevada limited liability company (“GBS LV”), and GB SCIENCES NEVADA LLC, a Nevada limited liability company (“GBS NV” and together with GBS LV, collectively, the “Borrower”) with their principal executive offices at 3550 W. Teco Avenue, Las Vegas NV 89 |
|
| August 28, 2020 |
MEMBERSHIP INTEREST PURCHASE AGREEMENT By and Among AJE MANAGEMENT, LLC (BUYER), GB SCIENCES LAS VEGAS, LLC, GB SCIENCES NEVADA, LLC and GB SCIENCES, INC. |
|
| August 28, 2020 |
FORM 10-K Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (Exact name o |
|
| August 28, 2020 |
Amendment to Note Documents between Registrant and CSW Ventures, LP dated July 12, 2019 AMENDMENT TO NOTE DOCUMENTS THIS AMENDMENT TO NOTE DOCUMENTS (this “Amendment”), dated as of July 12, 2019, is made and entered into on the terms and conditions hereinafter set forth, by and among GB SCIENCES, INC. |
|
| August 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2020 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission F |
|
| August 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 333-82580 CUSIP Number 361-544109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For period ended: June 30, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi |
|
| August 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 333-82580 CUSIP Number 361-544109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For period ended: March 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi |
|
| June 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission Fil |
|
| May 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission File |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2020 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission Fi |
|
| April 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2020 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission Fil |
|
| March 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2020 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission Fi |
|
| March 30, 2020 |
MEMBERSHIP INTEREST PURCHASE AGREEMENT By and Among AJE MANAGEMENT, LLC (BUYER), GB SCIENCES LAS VEGAS, LLC, GB SCIENCES NEVADA, LLC and GB SCIENCES, INC. |
|
| February 18, 2020 |
CONFIDENTIAL MEMBERSHIP INTEREST PURCHASE AGREEMENT among GB SCIENCES, INC. Seller, WELLCANA PLUS, LLC PURCHASER, GB SCIENCES LOUISIANA, LLC, and WELLCANA GROUP, LLC Dated as of November 15, 2019 MEMBERSHIP INTEREST PURCHASE AGREEMENT This Membership Interest Purchase Agreement (“Agreement”) is made as of November 15, 2019, among Wellcana Plus, LLC, a Louisiana limited liability company (“Purchase |
|
| February 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 333-82580 CUSIP Number 361-544109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For period ended: December 31, 2019 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Tr |
|
| February 18, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB |
|
| December 4, 2019 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2019 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission |
|
| November 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2019 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission |
|
| November 15, 2019 |
GBLX September 30, 2015 Form 10-Q (00170338).DOC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi |
|
| November 15, 2019 |
GBLX / GrowBlox Sciences, Inc. NT 10-Q - - NT 10-Q GBLX - Form 12b-25 (6/30/15 Form 10-Q) (00168471).DOCX UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 333-82580 CUSIP Number 361-544109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One):o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For period ended: September 30, 2019 o Transition Report on Form 10-K o Transition Re |
|
| November 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2019 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission |
|
| November 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2019 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commiss |
|
| October 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2019 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission |
|
| September 17, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2019 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission |
|
| September 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2019 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commissio |
|
| September 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2019 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission |
|
| August 21, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2019 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission F |
|
| August 15, 2019 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant Submission Proof - X:\2019 OPERATIONS\2019 EDGAR\07 July\Wall Street Media Co Inc\07-18-2019\Form 8-k\Draft\Production\Wall Street Media Co Inc Form 8-k. |
|
| August 15, 2019 |
Letter to Securities and Exchange Commission from Soles, Heyn & Company dated August 14, 2019 |
|
| August 15, 2019 |
GBLX / GrowBlox Sciences, Inc. NT 10-Q - - NT 10-Q GBLX - Form 12b-25 (6/30/15 Form 10-Q) (00168471).DOCX UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 333-82580 CUSIP Number 361-544109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One):o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For period ended: June 30, 2019 o Transition Report on Form 10-K o Transition Report |
|
| August 15, 2019 |
GBLX / GrowBlox Sciences, Inc. 10-Q - Quarterly Report - 10-Q GBLX September 30, 2015 Form 10-Q (00170338).DOC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| August 15, 2019 |
GBLX / GrowBlox Sciences, Inc. 10-Q/A - Quarterly Report - 10-Q/A GBLX September 30, 2015 Form 10-Q (00170338).DOC SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Amendment No. 1) (Mark One) ý QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commis |
|
| July 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2019 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Nevada (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission Fil |
|
| July 15, 2019 |
THIS NOTE AND THE UNDERLYING SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, (THE “ACT”) SHALL HAVE BECOME EFFECTIVE WITH RESPECT THERETO OR (ii) RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER THE ACT IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER NOR IS IN VIOLATION OF ANY APPLICABLE STATE SECURITIES LAWS. |
|
| July 15, 2019 |
GBLX / GrowBlox Sciences, Inc. 10-K - Annual Report - 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (Exact name of registrant as specified in |
|
| July 15, 2019 |
Subsidiaries of GB Sciences, Inc. GB Sciences, LLC GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC Growblox Life Sciences LLC GB Sciences Louisiana, LLC GB Sciences Texas LLC GB Sciences Nopah LLC GBS Global Biopharma, Inc. |
|
| July 15, 2019 |
Security Agreement between Registrant and CSW Ventures, LP dated February 28, 2019 SECURITY AGREEMENT This Security Agreement (this “Agreement”) is made and entered into effective as of March 1, 2019, by GB SCIENCES, INC. |
|
| July 15, 2019 |
Note Purchase Agreement between Registrant and Iliad Research and Trading, LP dated April 23, 2019 GB SCIENCES, INC. NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”), is entered into as of April 23, 2019 (the “Effective Date”), by and between GB Sciences, Inc., a Nevada corporation (the “Company”), and Iliad Research and Trading, L.P., a Utah limited partnership (the “Investor”). WHEREAS, the Company wishes to issue and sell to the Investor and the Investor wishes to purc |
|
| July 15, 2019 |
Asset Purchase Agreement between Registrant and GBS Global Biopharma, Inc. dated March 15, 2019 ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of March 15, 2019, by and between GB Sciences, Inc. |
|
| July 15, 2019 |
AGREEMENT WHEREAS, this Agreement (the “Agreement”) is made and entered into effective as of February 22, 2018, by and between GB SCIENCES, INC. |
|
| July 15, 2019 |
AMENDMENT AND TERMINATION AGREEMENT AMENDMENT AND TERMINATION AGREEMENT THIS AMENDMENT AND TERMINATION AGREEMENT (this “Amendment”) is entered into as of July , 2018, by and between GB Sciences, Inc. |
|
| July 15, 2019 |
Note Purchase Agreement between Registrant and CSW Ventures, LP dated February 28, 2019 GB SCIENCES, INC. NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”), is entered into as of February 28, 2019 (the “Effective Date”), by and among GB Sciences, Inc., a Nevada corporation (the “Company”), and CSW Ventures, LP (the “Investor”). WHEREAS, the Company wishes to issue and sell to the Investor and the Investor wishes to purchase from the Company a Senior Secured Conv |
|
| July 15, 2019 |
8% Convertible Promissory Note between Registrant and CSW Ventures, LP dated February 28, 2019 THIS NOTE AND THE UNDERLYING SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) SHALL HAVE BECOME EFFECTIVE WITH RESPECT THERETO OR (ii) RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER THE ACT IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER NOR IS IN VIOLATION OF ANY APPLICABLE STATE SECURITIES LAWS. |
|
| July 3, 2019 | ||
| July 2, 2019 |
GBLX / GrowBlox Sciences, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| July 1, 2019 |
GBLX / GrowBlox Sciences, Inc. NT 10-K - - NT 10-K GBLX - Form 12b-25 (6/30/15 Form 10-Q) (00168471).DOCX UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 333-82580 CUSIP Number 361-544109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One):x Form 10-K o Form 20-F o Form 11-K oForm 10-Q o Form 10-D o Form N-SAR o Form N-CSR For period ended: March 31, 2019 o Transition Report on Form 10-K o Transition Report |
|
| June 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2019 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission F |
|
| June 7, 2019 |
GBLX / GrowBlox Sciences, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| May 10, 2019 |
GBLX / GrowBlox Sciences, Inc. S-1/A S-1/A Registration No. 333-231218 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 /A (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GB SCIENCES, INC. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 1311 (Primary Standard Industrial Classification Code) 59-3733133 (I.R. |
|
| May 10, 2019 |
GBLX / GrowBlox Sciences, Inc. CORRESP - - GB SCIENCES, INC. May 10, 2019 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: GB Sciences, Inc. Registration Statement on Form S-1 (File No. 333-231218) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, GB Sciences, Inc. here |
|
| May 3, 2019 |
8% Convertible Promissory Note THIS NOTE AND THE UNDERLYING SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, (THE “ACT”) SHALL HAVE BECOME EFFECTIVE WITH RESPECT THERETO OR (ii) RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER THE ACT IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER NOR IS IN VIOLATION OF ANY APPLICABLE STATE SECURITIES LAWS. |
|
| May 3, 2019 |
GBLX / GrowBlox Sciences, Inc. S-1 S-1 Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GB SCIENCES, INC. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 1311 (Primary Standard Industrial Classification Code) 59-3733133 (I.R.S. Employer Identification Numbe |
|
| April 17, 2019 |
GBLX / GrowBlox Sciences, Inc. S-1/A Registration No. 333-230200 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 2 ) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GB SCIENCES, INC. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 1311 (Primary Standard Industrial Classification Code) 59-3733133 (I.R.S. |
|
| April 17, 2019 |
GB SCIENCES, INC. NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”), is entered into as of February 28, 2019 (the “Effective Date”), by and among GB Sciences, Inc., a Nevada corporation (the “Company”), and CSW Ventures, LP (the “Investor”). WHEREAS, the Company wishes to issue and sell to the Investor and the Investor wishes to purchase from the Company a Senior Secured Conv |
|
| April 17, 2019 |
8% Senior Secured Convertible Promissory Note THIS NOTE AND THE UNDERLYING SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) SHALL HAVE BECOME EFFECTIVE WITH RESPECT THERETO OR (ii) RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER THE ACT IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER NOR IS IN VIOLATION OF ANY APPLICABLE STATE SECURITIES LAWS. |
|
| April 17, 2019 |
GBLX / GrowBlox Sciences, Inc. CORRESP GB SCIENCES, INC. April 17, 2019 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: GB Sciences, Inc. Registration Statement on Form S-1 (File No. 333-230200) Request for Acceleration of Effective Date Ladies and Gentlemen: We have filed today our Amendment No. 2 to the referenced filing which responds to the oral comment |
|
| March 12, 2019 |
GBLX / GrowBlox Sciences, Inc. S-1/A Registration No. 333-230200 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GB SCIENCES, INC. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 1311 (Primary Standard Industrial Classification Code) 59-3733133 (I.R.S. |
|
| March 11, 2019 |
GBLX / GrowBlox Sciences, Inc. S-1 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GB SCIENCES, INC. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 1311 (Primary Standard Industrial Classification Code) 59-3733133 (I.R.S. Employer Identification |
|
| March 5, 2019 |
GBLX / GrowBlox Sciences, Inc. GB SCIENCES, INC. March 5, 2019 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: GB Sciences, Inc. Registration Statement on Form S-1 (File No. 333-227452) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, GB Sciences, Inc. her |
|
| February 27, 2019 |
GBLX / GrowBlox Sciences, Inc. S-1/A Registration No. 333-227452 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 3) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GB SCIENCES, INC. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 1311 (Primary Standard Industrial Classification Code) 59-3733133 (I.R.S. |
|
| February 27, 2019 |
GBLX / GrowBlox Sciences, Inc. Gary R Gary R. Henrie Attorney at Law P.O. Box 107 Telephone: 309-313-5092 Nauvoo, IL 62354 E-mail: [email protected] February 27, 2019 Via EDGAR THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance Washington, D.C. 20549 Re: GB Sciences, Inc. Amendment No. 2 to Registration Statement on Form S-1 Filed December 18, 2018 File No. 333-227452 To Whom It May Concern: A |
|
| February 19, 2019 |
GBLX / GrowBlox Sciences, Inc. 10-Q (Quarterly Report) GBLX September 30, 2015 Form 10-Q (00170338).DOC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commis |
|
| February 14, 2019 |
GBLX / GrowBlox Sciences, Inc. NT 10-Q GBLX - Form 12b-25 (6/30/15 Form 10-Q) (00168471).DOCX UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 333-82580 CUSIP Number 361-544109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One):o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For period ended: December 31, 2018 o Transition Report on Form 10-K o Transition Rep |
|
| December 18, 2018 |
GBLX / GrowBlox Sciences, Inc. S-1/A Registration No. 333-227452 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 2 ) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GB SCIENCES, INC. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 1311 (Primary Standard Industrial Classification Code) 59-3733133 (I.R.S. |
|
| December 18, 2018 |
GBLX / GrowBlox Sciences, Inc. Gary R Gary R. Henrie Attorney at Law P.O. Box 107 Telephone: 309-313-5092 Nauvoo, IL 62354 E-mail: [email protected] December 18, 2018 Via EDGAR THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance Washington, D.C. 20549 Re: GB Sciences, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed November 21, 2018 File No. 333-227452 To Whom It May Concern: A |
|
| November 21, 2018 |
GBLX / GrowBlox Sciences, Inc. S-1/A Registration No. 333- 227452 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 (Amendment No. 1) REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GB SCIENCES, INC. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 1311 (Primary Standard Industrial Classification Code) 59-3733133 (I.R.S. |
|
| November 21, 2018 |
GBLX / GrowBlox Sciences, Inc. Gary R. Henrie Attorney at Law P.O. Box 107 Telephone: 309-313-5092 Nauvoo, IL 62354 E-mail: [email protected] November 21, 2018 Via EDGAR THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance Washington, D.C. 20549 Re: GB Sciences, Inc. Registration Statement on Form S-1 Filed September 20, 2018 File No. 333-227452 To Whom It May Concern: As securities counsel to G |
|
| November 16, 2018 |
GBLX / GrowBlox Sciences, Inc. 10-Q/A (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Amendment No. 1) (Mark One) ý QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB |
|
| November 14, 2018 |
GBLX / GrowBlox Sciences, Inc. 10-Q (Quarterly Report) GBLX September 30, 2015 Form 10-Q (00170338).DOC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi |
|
| November 1, 2018 | ||
| November 1, 2018 |
GBLX / GrowBlox Sciences, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| October 25, 2018 |
GBLX / GrowBlox Sciences, Inc. S-8 S-1/A 1 a2141298zs-1a UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 22, 2018 |
GBLX / GrowBlox Sciences, Inc. PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| September 21, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2018 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commiss |
|
| September 21, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2018 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commiss |
|
| September 20, 2018 |
Subsidiaries of GB Sciences, Inc. GB Sciences, LLC GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC Growblox Life Sciences LLC GB Sciences Louisiana, LLC GB Sciences Texas LLC GB Sciences Nopah LLC |
|
| September 20, 2018 |
Powers of attorney (included in signature page) Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GB SCIENCES, INC. (Exact name of registrant as specified in its charter) NEVADA (State or other jurisdiction of incorporation or organization) 1311 (Primary Standard Industrial Classification Code) 59-3733133 (I.R.S. Employer Identification |
|
| September 20, 2018 |
Specimen Common Stock Certificate of Registrant Incorporated Under the Laws of the State of Nevada Number Shares Common Stock GB Sciences, Inc. |
|
| August 14, 2018 |
GBLX / GrowBlox Sciences, Inc. 10-Q (Quarterly Report) GBLX September 30, 2015 Form 10-Q (00170338).DOC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| August 14, 2018 |
Exhibit 3.4 |
|
| June 29, 2018 |
GBLX / GrowBlox Sciences, Inc. 10-K (Annual Report) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2018 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (Exact name of registrant as specified in |
|
| June 29, 2018 |
Subsidiaries of GB Sciences, Inc. GB Sciences, LLC GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC Growblox Life Sciences LLC GB Sciences Louisiana, LLC GB Sciences Texas LLC GB Sciences Nopah LLC |
|
| April 13, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2018 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission F |
|
| March 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2018 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission F |
|
| February 28, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2018 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commissi |
|
| February 14, 2018 |
GBLX / GrowBlox Sciences, Inc. 10-Q (Quarterly Report) GBLX September 30, 2015 Form 10-Q (00170338).DOC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2017 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commis |
|
| January 12, 2018 |
GBLX / GrowBlox Sciences, Inc. GBLX DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| December 22, 2017 |
GBLX / GrowBlox Sciences, Inc. GBLX PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| December 22, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* GB SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 361544 109 (CUSIP Number) December 7, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| November 20, 2017 |
GBLX / GrowBlox Sciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (E |
|
| November 16, 2017 |
GBLX / GrowBlox Sciences, Inc. GBLX 8-K APPOINTMENT OF NEW OFFICER (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2017 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commissi |
|
| November 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* GB SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 361544 109 (CUSIP Number) November 6, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| November 7, 2017 |
GBLX / GrowBlox Sciences, Inc. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC File Number 333-82580 CUSIP Number 361-544109 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One):o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For period ended: September 30, 2017 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Tr |
|
| August 14, 2017 |
GBLX / GrowBlox Sciences, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (Exact |
|
| August 8, 2017 |
GrowBlox Sciences GBLX DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| August 1, 2017 |
GrowBlox Sciences GBLX PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| July 14, 2017 |
GBLX / GrowBlox Sciences, Inc. 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No.1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2017 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (Exact n |
|
| July 12, 2017 |
GBLX / GrowBlox Sciences, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2017 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (Exact name of registrant a |
|
| July 12, 2017 |
Subsidiaries of GB Sciences, Inc. Exhibit 21.1 Subsidiaries of GB Sciences, Inc. GB Sciences Puerto Rico, LLC GB Sciences Puerto Rico, Inc. GB Sciences Florida, LLC GB Sciences Nevada, LLC GB Sciences New Jersey, LLC GB Sciences East, LLC GB Sciences, LLC GB Sciences Las Vegas, LLC Growblox Life Sciences, LLC |
|
| June 27, 2017 |
GrowBlox Sciences GBLX NT 10K MAR 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification of Late Filing SEC FILE NUMBER 000-55462 CUSIP NUMBER 361544 109 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ]Form N-CSR For Period Ended: March 31, 2017 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report o |
|
| June 21, 2017 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2017 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission F |
|
| May 31, 2017 |
GBLX / GrowBlox Sciences, Inc. / Lazarus Management Co LLC - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 14) Under the Securities Exchange Act of 1934 Growblox Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 399847 102 (CUSIP Nubmer) Adam D. Averbach, Esq. Lazarus Management Company LLC 3200 Cherry Creek South Drive, Suite 670 Denver, CO 80209 (303) 500-8821 (Name, Address a |
|
| May 31, 2017 |
EXHIBIT A JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the common stock of Growblox Sciences, Inc. |
|
| May 12, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2017 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commission Fil |
|
| February 16, 2017 |
GrowBlox Sciences GBLX 8-K/A (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2017 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commiss |
|
| February 14, 2017 |
GrowBlox Sciences 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GB SCIENCES, INC. (Ex |
|
| February 8, 2017 |
GBLX / GrowBlox Sciences, Inc. / Lazarus Management Co LLC - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 13) Under the Securities Exchange Act of 1934 Growblox Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 399847 102 (CUSIP Nubmer) Adam D. Averbach, Esq. Lazarus Management Company LLC 3200 Cherry Creek South Drive, Suite 670 Denver, CO 80209 (303) 500-8821 (Name, Address a |
|
| February 8, 2017 |
EXHIBIT A JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the common stock of Growblox Sciences, Inc. |
|
| February 8, 2017 |
EXHIBIT B TRANSACTIONS The following table sets forth all transactions with respect to shares of common stock effected during the past 60 days by the Reporting Persons or on behalf of the Reporting Persons in respect of the shares of common stock, inclusive of any transactions effected through the close of trading on February 7, 2017. |
|
| January 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2017 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commissio |
|
| December 20, 2016 |
GrowBlox Sciences GBLX 8K AMEND CERT OF INCORP (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2016 GB Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commissi |
|
| December 20, 2016 |
STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION The corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify: FIRST: That at a meeting of the Board of Directors of Growblox Sciences, Inc. |
|
| November 18, 2016 |
GBLX / GrowBlox Sciences, Inc. / Lazarus Management Co LLC - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 12) Under the Securities Exchange Act of 1934 Growblox Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 399847 102 (CUSIP Nubmer) Adam D. Averbach, Esq. Lazarus Management Company LLC 3200 Cherry Creek South Drive, Suite 670 Denver, CO 80209 (303) 500-8821 (Name, Address a |
|
| November 18, 2016 |
EXHIBIT A JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the common stock of Growblox Sciences, Inc. |
|
| November 14, 2016 |
Exhibit 10.1 AMENDED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (" Agreement") is made and entered into as of the 7 th day of October, 2016 by and between Growblox Science, Inc., a Delaware corporation (hereinafter), called the " Company") and Ksenia Griswold (hereinafter called the " Executive"). A. The Company and the Executive entered into an employment agreement dated |
|
| November 14, 2016 |
GrowBlox Sciences 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GROWBLOX SCIENCES, I |
|
| November 10, 2016 |
GBLX / GrowBlox Sciences, Inc. / Pershing Edward - EDWARD PERSHING 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* GROWBLOX SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 399847 102 (CUSIP Number) November 2, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| November 10, 2016 |
GBLX / GrowBlox Sciences, Inc. / MOODY ROBERT JR - SCHEDULE 13G ROBERT MOODY JR Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* GROWBLOX SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 399847 102 (CUSIP Number) September 7, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| November 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* GROWBLOX SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 399847 102 (CUSIP Number) August 8, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| November 8, 2016 |
GBLX / GrowBlox Sciences, Inc. / Ruggieri David - SC 13G DR. DAVE RUGGIERI Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* GROWBLOX SCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 399847 102 (CUSIP Number) June 15, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| October 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2016 Growblox Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Comm |
|
| October 12, 2016 |
GBLX / GrowBlox Sciences, Inc. / Lazarus Management Co LLC - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 11) Under the Securities Exchange Act of 1934 Growblox Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 399847 102 (CUSIP Nubmer) Adam D. Averbach, Esq. Lazarus Management Company LLC 3200 Cherry Creek South Drive, Suite 670 Denver, CO 80209 (303) 500-8821 (Name, Address a |
|
| October 12, 2016 |
EXHIBIT A JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the common stock of Growblox Sciences, Inc. |
|
| October 12, 2016 |
EXHIBIT B TRANSACTIONS The following table sets forth all transactions with respect to shares of common stock effected since the Schedule 13D filing on September 13, 2016 by the Reporting Persons or on behalf of the Reporting Persons in respect of the shares of common stock, inclusive of any transactions effected through the close of trading on October 11, 2016. |
|
| October 7, 2016 |
EXHIBIT A JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the common stock of Growblox Sciences, Inc. |
|
| October 7, 2016 |
GBLX / GrowBlox Sciences, Inc. / Lazarus Management Co LLC - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 10) Under the Securities Exchange Act of 1934 Growblox Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 399847 102 (CUSIP Nubmer) Adam D. Averbach, Esq. Lazarus Management Company LLC 3200 Cherry Creek South Drive, Suite 670 Denver, CO 80209 (303) 500-8821 (Name, Address a |
|
| October 7, 2016 |
EXHIBIT B TRANSACTIONS The following table sets forth all transactions with respect to shares of common stock effected since the most recent Schedule 13D filing on September 13, 2016 by the Reporting Persons or on behalf of the Reporting Persons in respect of the shares of common stock, inclusive of any transactions effected through the close of trading on October 6, 2016. |
|
| September 13, 2016 |
GBLX / GrowBlox Sciences, Inc. / Lazarus Management Co LLC - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 9) Under the Securities Exchange Act of 1934 Growblox Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 399847 102 (CUSIP Nubmer) Adam D. Averbach, Esq. Lazarus Management Company LLC 3200 Cherry Creek South Drive, Suite 670 Denver, CO 80209 (303) 500-8821 (Name, Address an |
|
| September 9, 2016 |
GrowBlox Sciences GBLX 8-K STOCK ISSUANCE (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2016 Growblox Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Co |
|
| August 26, 2016 |
GrowBlox Sciences GBLX DEF 14A ANNUAL MEETING 2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| August 26, 2016 |
GrowBlox Sciences GBLX DEF 14A ANNUAL MEETING 2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| August 26, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) GrowBlox Sciences, Inc. (Name of Issuer) Common Stock, $.0001 Par Value per share (Title of Class of Securities) 399847102 (CUSIP Number) Augu |
|
| August 26, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) GrowBlox Sciences, Inc. (Name of Issuer) Common Stock, $.0001 Par Value per share (Title of Class of Securities) 399847102 (CUSIP Number) Augu |
|
| August 19, 2016 |
GBLX / GrowBlox Sciences, Inc. / Lazarus Management Co LLC - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 8) Under the Securities Exchange Act of 1934 Growblox Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 399847 102 (CUSIP Nubmer) Adam D. Averbach, Esq. Lazarus Management Company LLC 3200 Cherry Creek South Drive, Suite 670 Denver, CO 80209 (303) 500-8821 (Name, Address an |
|
| August 19, 2016 |
GBLX / GrowBlox Sciences, Inc. / Lazarus Management Co LLC - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 8) Under the Securities Exchange Act of 1934 Growblox Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 399847 102 (CUSIP Nubmer) Adam D. Averbach, Esq. Lazarus Management Company LLC 3200 Cherry Creek South Drive, Suite 670 Denver, CO 80209 (303) 500-8821 (Name, Address an |
|
| August 15, 2016 |
Exhibit 10.1 SECOND OMNIBUS AMENDMENT THIS SECOND OMNIBUS AMENDMENT (this " Amendment") is entered into as of August 4, 2016 (the " Amendment Date"), between Growblox Sciences, Inc., a Delaware corporation (the " Company"), GB Sciences Nevada LLC, a Nevada limited liability company (" GBS Nevada ") and Pacific Leaf Ventures, LP (the " Investor"). R E C I T A L S A. The Company and the Investor are |
|
| August 15, 2016 |
GrowBlox Sciences 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GROWBLOX SCIENCES, INC. ( |
|
| August 15, 2016 |
Exhibit 10.1 SECOND OMNIBUS AMENDMENT THIS SECOND OMNIBUS AMENDMENT (this " Amendment") is entered into as of August 4, 2016 (the " Amendment Date"), between Growblox Sciences, Inc., a Delaware corporation (the " Company"), GB Sciences Nevada LLC, a Nevada limited liability company (" GBS Nevada ") and Pacific Leaf Ventures, LP (the " Investor"). R E C I T A L S A. The Company and the Investor are |
|
| August 15, 2016 |
GrowBlox Sciences 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55462 GROWBLOX SCIENCES, INC. ( |
|
| August 12, 2016 |
GrowBlox Sciences GBLX PRE 14A (2016 ANNUAL MEETING) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| August 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 Or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2016 Growblox Sciences, Inc. (Exact name of Registrant as specified in its charter) Delaware (State or other Jurisdiction of Incorporation or organization) 000-55462 (Commi |
|
| July 18, 2016 |
GBLX / GrowBlox Sciences, Inc. / Lazarus Management Co LLC - SCHEDULE 13D/A Activist Investment lazarus_13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 7) Under the Securities Exchange Act of 1934 Growblox Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 399847 102 (CUSIP Nubmer) Adam D. Averbach, Esq. Lazarus Management Company LLC 3200 Cherry Creek South Drive, Suite 670 Denver, CO 80209 (303) 500-8821 ( |
|
| July 15, 2016 |
GrowBlox Sciences 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No.1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2016 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-55462 GROWBLOX SCIENCES, INC. (E |
|
| July 14, 2016 |
EX-10.23 2 ex1023.htm EXHIBIT 10.23 Exhibit 10.23 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT ("Agreement") is made and entered into as of the 31th day of May, 2016 by and between Growblox Science, Inc., a Delaware corporation (hereinafter), called the "Company") and John Poss (hereinafter called the "Executive"). A. The Company and the Executive entere |
|
| July 14, 2016 |
Exhibit 10.24 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (" Agreement") is made and entered into as of the 24 th day of May, 2016 by and between Growblox Science, Inc., a Delaware corporation (hereinafter), called the "Company") and Andrea Small-Howard (hereinafter called the "Executive"). A. The Company and the Executive entered into an employment agr |
|
| July 14, 2016 |
GrowBlox Sciences 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2016 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number: 000-55462 GROWBLOX SCIENCES, INC. (Exact name of regist |
|
| July 14, 2016 |
Exhibit 10.26 Compensation Committee Charter As of June 2016 I. PURPOSE The purpose of the Compensation Committee of the Board of Directors (the "Board") of Growblox Sciences, Inc., a Delaware corporation (the "Company") shall be to review and make recommendations to the Board regarding all forms of compensation to be provided to the executive officers and directors of the Company, including witho |
|
| July 14, 2016 |
Exhibit 10.25 Audit Committee Charter As of June 2016 I. PURPOSE The purpose of the Audit Committee of the Board of Directors (the "Board") of Growblox Sciences Inc., a Delaware corporation (the "Company") shall be: · to provide oversight and monitoring of (i) the Company's financial reporting process (ii) the Company's systems of internal controls over financial reporting, (iii) the integrity of |
|
| July 14, 2016 |
Subsidiaries of Growblox Sciences, Inc. Exhibit 21.1 Subsidiaries of Growblox Sciences, Inc. GB Sciences Puerto Rico, LLC GB Sciences Puerto Rico, Inc. GB Sciences Florida, LLC GB Sciences Nevada, LLC GB Sciences New Jersey, LLC GB Sciences East, LLC GB Sciences, LLC |
|
| June 29, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 Notification of Late Filing SEC FILE NUMBER 000-55462 CUSIP NUMBER 399847 10 2 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ]Form N-CSR For Period Ended: March 31, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report |
